- Report
- January 2023
- 150 Pages
Global
From €5276EUR$5,950USD£4,574GBP
- Report
- December 2022
- 109 Pages
Japan
From €1596EUR$1,800USD£1,384GBP
- Report
- December 2023
- 153 Pages
Global
From €2195EUR$2,475USD£1,903GBP
€4389EUR$4,950USD£3,805GBP
- Report
- December 2023
- 155 Pages
Global
From €2195EUR$2,475USD£1,903GBP
€4389EUR$4,950USD£3,805GBP
- Report
- April 2024
- 279 Pages
Global
From €4433EUR$5,000USD£3,844GBP
- Report
- May 2024
- 277 Pages
Global
From €4433EUR$5,000USD£3,844GBP
- Report
- August 2022
- 120 Pages
Global
From €3990EUR$4,500USD£3,459GBP
- Report
- July 2024
- 150 Pages
Global
From €3325EUR$3,750USD£2,883GBP
- Report
- January 2022
- 90 Pages
Global
From €1773EUR$2,000USD£1,537GBP
- Report
- January 2022
- 125 Pages
Global
From €2217EUR$2,500USD£1,922GBP
- Report
- January 2022
- 90 Pages
Global
From €1773EUR$2,000USD£1,537GBP
- Report
- January 2022
- 90 Pages
Global
From €1773EUR$2,000USD£1,537GBP
- Report
- January 2022
- 150 Pages
Global
From €1330EUR$1,500USD£1,153GBP
- Report
- January 2022
- 70 Pages
Global
From €887EUR$1,000USD£769GBP
- Report
- January 2022
- 70 Pages
Global
From €887EUR$1,000USD£769GBP
- Report
- August 2024
- 136 Pages
Global
From €2659EUR$2,999USD£2,305GBP
- Report
- April 2024
- 135 Pages
Global
From €2659EUR$2,999USD£2,305GBP
- Report
- March 2024
- 138 Pages
Global
From €2659EUR$2,999USD£2,305GBP
- Report
- March 2023
- 350 Pages
Europe
From €2659EUR$2,999USD£2,305GBP
- Report
- April 2025
- 85 Pages
India
From €3103EUR$3,500USD£2,691GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more